Skip to content

The effect of Remimazolam on perioperative myocardial injury in patients with ischemic heart disease

The effect of Remimazolam on perioperative myocardial injury in patients with ischemic heart disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065821
Enrollment
Unknown
Registered
2022-11-16
Start date
2022-11-20
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic heart disease

Interventions

Remimazolam Group:Remimazolam 0.2 mg/kg IV bolus
Control group:Conventional general anesthesia with propofol

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of ischemic heart disease, and the condition is stable; Ischemic heart disease includes the following clinical types: (1) Arteriosclerotic heart disease; (2) Stable angina pectoris; (3) Old myocardial infarction: myocardial infarction diagnosed by electrocardiogram or other special examination in the past, but no symptoms in the near future; (4) Cardiac aneurysm; (5) Coronary artery aneurysm: coronary artery arteriovenous fistula, acquired. Excludes: Congenital coronary (arterial) aneurysm (Q24.5); (6) Ischemic cardiomyopathy; (7) Silent myocardial ischemia; 2. All patients underwent elective non-cardiac surgery under general anesthesia; 3. United States Society of Anesthesiologists (ASA) classification <= III, and new York Heart Association (NYHA) classification <= II; 4. There were no serious lesions of heart, lung, brain and other important organs before operation, and no obvious abnormality of liver and kidney function; 5. Clearly understand the study content and voluntarily participate in the study before operation, and sign the informed consent form for the study.

Exclusion criteria

Exclusion criteria: 1. Patients with recent (within 6 months) aggravated heart disease; 2. Cardiac dysplasia; 3. Severe infection, shock or dysfunction of important organs; 4. Preoperative state of consciousness, mental state and central nervous system disorders; 5. Severe arrhythmia and anemia (Hb <= 60g/L) before operation; 6. History of severe allergy to the study drug.

Design outcomes

Primary

MeasureTime frame
Myocardial injury markers;

Secondary

MeasureTime frame
Hemoglobin;Visual Analogue Score;

Countries

China

Contacts

Public ContactChen Yanhua

The First Affiliated Hospital of Guangxi Medical University

402009694@qq.com+86 13978858025

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026